Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Dosage Charts  ›  FOXO4-DRI
Longevity

FOXO4-DRI Guide & Dosage Chart

A peptide studied for senolytic clearance of senescent cells.

Routesubcutaneous
FOXO4-DRI — Dosage chart
Every row cited
GoalDoseFrequencyDurationEvidenceSource
Cited dosing data is being compiled for this compound.
For research and educational use only. Not medical advice.

What is FOXO4-DRI?

FOXO4-DRI is a synthetic research peptide designed to selectively eliminate a specific type of damaged cell called a senescent cell. Senescent cells are sometimes called "zombie cells" — they stop dividing normally, yet refuse to die. Instead, they linger in tissues and pump out a cocktail of inflammatory signals that can harm surrounding healthy cells over time.

The "DRI" part of the name stands for D-retro-inverso — a clever chemical trick where the amino acids are built in mirror-image form and strung together backwards. This makes the peptide much harder for the body to break down than a normal protein would be.

FOXO4-DRI belongs to a class of compounds called senolytics — agents studied for their ability to clear senescent cells. It sits in the Longevity category of research peptides, and scientists are investigating whether clearing these zombie cells could help restore healthier tissue function in aging.

How FOXO4-DRI Works

Here is a simple analogy. Imagine senescent cells as stubborn squatters who have overstayed their welcome in a building. Normally a security protein called p53 would evict them (trigger their self-destruct sequence, known as apoptosis). But another protein, FOXO4, acts like a corrupt landlord — it grabs p53 inside the cell's nucleus and stops it from doing its job. The squatters stay put.

FOXO4-DRI mimics part of the FOXO4 protein. It slips into senescent cells and outcompetes the real FOXO4 for the binding spot on p53.[5] Once FOXO4-DRI has blocked that interaction, p53 is free to move out of the nucleus and trigger the cell's self-destruct sequence — but only in senescent cells, because healthy cells rely on different survival pathways.[3]

A 2025 structural study used NMR imaging to map exactly how this happens at the molecular level. Researchers found that FOXO4-DRI binds directly to a flexible, disordered region of p53 called the transactivation domain 2, and that phosphorylation (a chemical tag) on p53 actually increases how tightly FOXO4-DRI grabs on.[5]

What the Research Shows

Most FOXO4-DRI studies so far have been conducted in cell cultures and rodent models. Here is a plain-language summary of what researchers have found:

  • Male reproductive aging (mice): Aged male mice treated with FOXO4-DRI showed improved testosterone levels. The peptide selectively triggered apoptosis in senescent Leydig cells — the testicular cells that make testosterone — and improved the overall testicular environment.[3] A follow-up study found that clearing these senescent Leydig cells also reduced their toxic secretions, which in turn improved sperm quality and spermatogenesis in aged mice.[2]
  • Keloid scarring (cells and tissue): Keloids are raised, aggressive scars that are notoriously hard to treat. A 2025 study found that keloid tissue is packed with senescent fibroblasts (connective tissue cells stuck in a zombie state). FOXO4-DRI pushed p53 out of the nucleus of these cells and triggered their apoptosis, suggesting the peptide could potentially target the senescent environment that drives keloid growth and relapse.[1]
  • Endothelial cell senescence: Endothelial cells line blood vessels. Recent research demonstrated that FOXO4-DRI can regulate senescence in these cells through the p53 signaling pathway, pointing to possible relevance for vascular aging research.[6]
  • An important caution — pulmonary hypertension: Not all senescent cells are harmful. A significant 2023 study published in Circulation found that when senolytic interventions — including FOXO4-DRI — were used in mouse models of pulmonary hypertension, they actually worsened lung blood pressure and damaged pulmonary endothelial cells. The researchers concluded that some senescent cells in the lung vasculature may play a protective role.[4] This is a critical reminder that senolytics are not universally beneficial and that context matters enormously.

What FOXO4-DRI Is Being Studied For

Based on published preclinical research, FOXO4-DRI is being explored as a tool to understand:

  • Senescent cell biology and the FOXO4-p53 interaction[5]
  • Age-related hormonal decline and male reproductive aging[2][3]
  • Pathological scarring driven by fibroblast senescence[1]
  • Vascular aging and endothelial senescence[6]
  • The broader question of when clearing senescent cells helps — and when it might harm[4]

It is strictly a research compound. It is not approved for human use, and nothing here should be read as medical advice.

How FOXO4-DRI Is Dosed in Research

Dosing protocols for FOXO4-DRI vary across published studies and depend heavily on the research model being used. Because no standardized human dosing exists, we have compiled the protocols reported in preclinical literature into the dosage chart on this page. You can also use the calculator to convert between common research units. Always consult the specific study methods most relevant to your research model before proceeding.

Mixing and Storing FOXO4-DRI

FOXO4-DRI is typically supplied as a lyophilized (freeze-dried) white powder. To reconstitute it, researchers generally add a small volume of sterile water or a dilute acetic acid solution (around 0.1–1%) to the vial, then swirl gently — never shake vigorously, as this can break the peptide's structure. Once dissolved, the solution can be further diluted with sterile phosphate-buffered saline (PBS) to the desired working concentration. Aliquot the solution into small single-use portions to avoid repeated freeze-thaw cycles, which degrade peptide integrity. Store lyophilized powder at −20 °C or colder, protected from light and moisture. Reconstituted solutions should be kept at −80 °C for long-term storage, or at 4 °C for short-term use of a few days. Always label vials with the date of reconstitution.

Sources

  1. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. — Communications biology, 2025. PMID 39994346.
  2. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. — Experimental gerontology, 2024. PMID 39025385.
  3. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. — Aging, 2020. PMID 31959736.
  4. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. — Circulation, 2023. PMID 36515093.
  5. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. — Nature communications, 2025. PMID 40593617.
  6. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. — Frontiers in bioengineering and biotechnology, 2025. PMID 41625068.

FOXO4-DRI FAQ

What is FOXO4-DRI?
FOXO4-DRI is a synthetic research peptide engineered to selectively trigger self-destruction (apoptosis) in senescent — or "zombie" — cells. It is built using a D-retro-inverso modification, making it resistant to normal protein breakdown. It is classified as a senolytic compound and is studied in the longevity research field. It is not approved for human therapeutic use.[3][5]
How does FOXO4-DRI work?
In senescent cells, a protein called FOXO4 locks onto p53 inside the nucleus and prevents the cell from dying. FOXO4-DRI mimics part of FOXO4 and competes for that same binding spot on p53. When FOXO4-DRI wins, p53 is freed, moves out of the nucleus, and triggers the senescent cell's self-destruct sequence. Healthy cells are largely unaffected because they use different survival signals.[3][5]
What is FOXO4-DRI used for in research?
Researchers are studying FOXO4-DRI as a tool to clear senescent cells in aging tissue. Preclinical studies have explored its effects on age-related testosterone decline[3], sperm quality in aged mice[2], keloid scar fibroblasts[1], and endothelial cell senescence[6]. Importantly, one study found senolytic use worsened pulmonary hypertension in mice, highlighting that context matters.[4]
How is FOXO4-DRI dosed in research studies?
Dosing varies widely depending on the research model, species, and endpoint being studied. No standardized human dosing protocol exists. Preclinical protocols are summarized in the dosage chart on this page, and you can convert units using the calculator. Always refer to the primary literature for the model closest to your own research application.
How do you reconstitute FOXO4-DRI?
FOXO4-DRI powder is typically dissolved in sterile water or a dilute acetic acid solution (0.1–1%), then gently swirled — not shaken — until clear. It can then be diluted with sterile PBS. Aliquot into small portions to avoid repeated freeze-thaw cycles. Store reconstituted solution at −80 °C for long-term use or at 4 °C for use within a few days.
Is FOXO4-DRI safe?
FOXO4-DRI has not been approved for human use and its safety profile in humans is unknown. Even in preclinical research, results are mixed — one study found that senolytic interventions including FOXO4-DRI worsened pulmonary hypertension and damaged protective endothelial cells in mouse lung tissue.[4] This compound is for research purposes only. Never use it as a medical treatment.